Effectiveness and safety of monoclonal antibodies against amyloid-beta vis-à-vis placebo in mild or moderate Alzheimer's disease

BACKGROUNDS AND OBJECTIVES: Currently, no consensus has been reached on the therapeutic implications of monoclonal antibodies against amyloid-beta (Aβ) in Alzheimer's disease (AD). This study aimed to examine the effectiveness and safety of monoclonal antibodies against Aβ as a whole and also t...

Descripción completa

Detalles Bibliográficos
Autores principales: Hao, Ying, Dong, Mingrui, Sun, Yingtong, Duan, Xiaohui, Niu, Wenquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050585/
https://www.ncbi.nlm.nih.gov/pubmed/37006475
http://dx.doi.org/10.3389/fneur.2023.1147757

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050585/
https://www.ncbi.nlm.nih.gov/pubmed/37006475
http://dx.doi.org/10.3389/fneur.2023.1147757

Ejemplares similares